These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9858968)

  • 1. [Interview with S. Lévy. Apropos of recommendations on defibrillators. Interview by M. Hérida].
    Lévy S
    Presse Med; 1998 Nov; 27(37):1907-8. PubMed ID: 9858968
    [No Abstract]   [Full Text] [Related]  

  • 2. Implantable defibrillators and sudden cardiac death.
    Josephson M; Wellens HJ
    Circulation; 2004 Jun; 109(22):2685-91. PubMed ID: 15184292
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatable causes of sudden death: not really "treatable" or not really the cause?
    Viskin S; Halkin A; Olgin JE
    J Am Coll Cardiol; 2001 Nov; 38(6):1725-7. PubMed ID: 11704387
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidemiological impact of microvolt T-wave alternans in sudden cardiac death primary prevention.
    Daccarett M; Serafimovski N; Machado C
    Int J Cardiol; 2007 Jun; 119(1):127-8; author reply 129-30. PubMed ID: 17049385
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of implantable cardioverter-defibrillators.
    Boriani G; Biffi M; Martignani C; Gallina M; Branzi A
    Eur Heart J; 2001 Jun; 22(12):990-6. PubMed ID: 11428834
    [No Abstract]   [Full Text] [Related]  

  • 6. Mortality benefits and the implantable cardioverter-defibrillator.
    Sweeney MO; Ruskin JN
    Circulation; 1994 Apr; 89(4):1851-8. PubMed ID: 8149550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention.
    Ye S; Grunnert M; Thune JJ; Stephenson KM; Uno H; Finn PV; McMurray JJ; Velazquez EJ; Califf R; Pfeffer MA; Solomon SD
    Circulation; 2011 Jun; 123(23):2674-80. PubMed ID: 21606398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AICD automatic cardioverter defibrillator clinical update: 14 years experience in over 34,000 patients.
    Nisam S; Kaye SA; Mower MM; Hull M
    Pacing Clin Electrophysiol; 1995 Jan; 18(1 Pt 2):142-7. PubMed ID: 7724388
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized clinical trials: how long should they last?
    Wellens HJ
    Circulation; 2004 Jul; 110(2):107-8. PubMed ID: 15249514
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar?
    Nishimura RA; Ommen SR
    JAMA; 2007 Jul; 298(4):452-4. PubMed ID: 17652299
    [No Abstract]   [Full Text] [Related]  

  • 11. [Implantable defibrillators--current status of guidelines. Recognized and possible indications--prerequisites].
    Andresen D
    Fortschr Med; 1996 Apr; 114(11):128-32. PubMed ID: 8682425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of sudden cardiac death: the role of the implantable cardioverter-defibrillator.
    Sinha SK; Mehta D; Gomes JA
    Mt Sinai J Med; 2005 Jan; 72(1):1-9. PubMed ID: 15682255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertrophic cardiomyopathy with midcavitary obstruction: another substrate for ventricular tachycardia?
    Gerstenfeld EP
    J Cardiovasc Electrophysiol; 2010 Sep; 21(9):1000-1. PubMed ID: 20487115
    [No Abstract]   [Full Text] [Related]  

  • 14. Appropriate use of the implantable cardioverter defibrillator: a Canadian perspective. Canadian Working Group on Cardiac Pacing.
    Yee R; Connolly SJ; Gillis AM
    Pacing Clin Electrophysiol; 1999 Jan; 22(1 Pt 1):1-4. PubMed ID: 9990594
    [No Abstract]   [Full Text] [Related]  

  • 15. Food for afterthought: reflections from 2 implantable cardioverter defibrillator trials.
    Rahimtoola SH
    Arch Intern Med; 2004 Sep; 164(17):1835-9. PubMed ID: 15451756
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevention of sudden death and the countermeasures--implantable defibrillators].
    Kasanuki H
    Nihon Naika Gakkai Zasshi; 1998 Jan; 87(1):105-16. PubMed ID: 9513555
    [No Abstract]   [Full Text] [Related]  

  • 17. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malignant mitral valve prolapse: apropos of a case].
    Van Caenegem O; Chaudron JM; Scavée C; de Meester A
    Acta Clin Belg; 1996; 51(6):403-8. PubMed ID: 9027190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillator: present and future indications.
    Block M; Scheld H; Breithardt G
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():141-7. PubMed ID: 8734176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the main implantable cardioverter-defibrillator trials and the 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
    Proclemer A; Ghidina M
    J Cardiovasc Med (Hagerstown); 2007 May; 8(5):320-3. PubMed ID: 17443096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.